Kim Sol-Ji, Yeo Ji-Hee, Yoon Seo-Yeon, Roh Dae-Hyun
Department of Oral Physiology, College of Dentistry, Kyung Hee University, Seoul 02447, Republic of Korea.
Department of Companion Animals, Yuhan University, Bucheon-si, Gyeonggi-do 14780, Republic of Korea.
Integr Med Res. 2023 Dec;12(4):100999. doi: 10.1016/j.imr.2023.100999. Epub 2023 Oct 20.
Peripheral hypersensitivities develop in the face and hindpaws of mice with nitroglycerin (NTG)-induced migraine. We evaluated whether diluted bee venom (DBV) injections at acupoints prevented these peripheral hypersensitivities and c-Fos expression in the trigeminal nucleus caudalis (TNC).
NTG (10 mg/kg, intraperitoneal, i.p.) was administered every other day for nine days. DBV (0.1 mg/kg) was subcutaneously injected into the ST36 (Zusanli), LI4 (Hegu), or GV16 (Fengfu) acupoints 75 min after each NTG injection. Mice were pretreated with naloxone (5 mg/kg, i.p.) or yohimbine (5 mg/kg, i.p.) 30 min before the DBV injections.
NTG injection caused facial cold allodynia, hindpaw mechanical allodynia, and increased c-Fos-immunoreactive (ir) cells in the TNC. Repetitive DBV injections at GV16, but not the ST36, or LI4 acupoints, suppressed NTG-induced hindpaw mechanical allodynia and facial cold allodynia. The number of c-Fos-ir cells also decreased in response to DBV injections at the GV16 acupoint. Remarkably, pretreatment with yohimbine reversed the anti-allodynic effects of DBV injections and attenuated the decreased c-Fos expression in response to GV16 DBV treatment. Naloxone did not block the effects of GV16 DBV stimulation.
These findings demonstrate that repetitive DBV treatment at the GV16 acupoint relieves NTG-induced facial and hindpaw hypersensitivities and decreases in c-Fos expression in the TNC via activation of the alpha-2 adrenoceptors, but not the opioid receptors.
在硝酸甘油(NTG)诱导偏头痛的小鼠面部和后爪会出现外周超敏反应。我们评估了穴位注射稀释蜂毒(DBV)是否能预防这些外周超敏反应以及三叉神经尾核(TNC)中c-Fos的表达。
每隔一天腹腔注射NTG(10mg/kg),共注射九天。每次NTG注射75分钟后,将DBV(0.1mg/kg)皮下注射到足三里(ST36)、合谷(LI4)或风府(GV16)穴位。在注射DBV前30分钟,小鼠腹腔注射纳洛酮(5mg/kg)或育亨宾(5mg/kg)进行预处理。
NTG注射导致面部冷觉异常性疼痛、后爪机械性异常性疼痛,并增加了TNC中c-Fos免疫反应性(ir)细胞。在GV16穴位重复注射DBV可抑制NTG诱导的后爪机械性异常性疼痛和面部冷觉异常性疼痛,而在ST36或LI4穴位注射则无此效果。在GV16穴位注射DBV后,c-Fos-ir细胞数量也减少。值得注意的是,育亨宾预处理可逆转DBV注射的抗异常性疼痛作用,并减弱GV16穴位注射DBV后c-Fos表达的降低。纳洛酮并未阻断GV16穴位注射DBV的作用。
这些发现表明,在GV16穴位重复注射DBV可通过激活α-2肾上腺素能受体而非阿片受体,缓解NTG诱导的面部和后爪超敏反应,并减少TNC中c-Fos的表达。